HRS-8080

HRS-8080 is a small-molecule drug developed by Shandong Suncadia Medicine. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: * HRS-8080 Tablet * Dalpiciclib Isethionate. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07354022 (A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy), NCT07024173 (A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer) and NCT07349069 (A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT07349069, plans to enrol 5500 participants with primary completion expected 2030-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.